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 INTRODUCTION
 Th e absence of reliable blood markers for pancreatic ductal 
adenocarcinoma (PDAC) reduces the potential eff ectiveness 
of screening strategies in at-risk populations such as those with 
chronic pancreatitis (CP). Furthermore, among individuals with 
PDAC, there are no histological or molecular targets currently 
applied in the clinical setting to direct therapy or inform survival 
estimates. Th erefore, the discovery of biomarkers derived from 
blood or bile that facilitate the distinction of PDAC from CP 
and provide prognostic information for individuals with PDAC 
 A Pilot Study to Develop a Diagnostic Test for 
Pancreatic Ductal Adenocarcinoma Based on 
Differential Expression of Select miRNA in Plasma 
and Bile
 Gregory A.  Cote ,  MD, MS 1  ,  4 ,  A. Jesse  Gore ,  PhD 2  ,  4 ,  Samantha D.  McElyea ,  MS 2 ,  Laura E.  Heathers ,  BA 1 ,  Huiping  Xu ,  PhD 3 , 
 Stuart  Sherman ,  MD 1 and  Murray  Korc ,  MD 2 
 OBJECTIVES:  Accurate peripheral markers for the diagnosis of pancreatic ductal adenocarcinoma (PDAC) are 
lacking. We measured the differential expression of select microRNAs (miRNAs) in plasma and 
bile among patients with PDAC, chronic pancreatitis (CP), and controls.
 METHODS:  We identiﬁ ed patients ( n =215) with treatment-naive PDAC ( n =77), CP with bile/pancreatic duct 
pathology ( n =67), and controls ( n =71) who had been prospectively enrolled in a Pancreatobiliary 
Biorepository at the time of endoscopic retrograde cholangiopancreatography or endoscopic 
ultrasound. Controls were patients with choledocholithiasis but normal pancreata. The sample 
was separated into training ( n =95) and validation ( n =120) cohorts to establish and then test the 
performance of PDAC Signature Panels in diagnosing PDAC. The training cohort ( n =95) included 
age-matched patients with PDAC, CP, and controls. Panels were derived from the differential 
expression of 10 candidate miRNAs in plasma or bile. We selected miRNAs having excellent 
accuracy for inclusion in regression models.
 RESULTS:  Using the training cohort, we conﬁ rmed the differential expression of 9/10 miRNAs in plasma 
(miR-10b, -30c, -106b, -132, -155, -181a, -181b, -196a, and -212) and 7/10 in bile (excluding 
miR-21, -132, and -181b). Of these, ﬁ ve (miR-10b, -155, -106b, -30c, and -212) had excellent 
accuracy for distinguishing PDAC. In the training and validation cohorts, the sensitivity/speciﬁ city for 
a PDAC Panel derived from plasma was 95/100% and 100/100%, respectively; in bile, these were 
96/100% and 100/100%.
 CONCLUSIONS:  Increased expression of miRNA-10b, -155, and -106b in plasma appears highly accurate in 
diagnosing PDAC. Additional studies are needed to conﬁ rm this Panel and explore its value as a 
prognostic test.
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would greatly aff ect patient management. In addition, biomarkers 
may guide studies designed to elucidate dysplasia-to-carcinoma 
mechanism(s) specifi c to PDAC and identify gene or protein tar-
gets for novel therapies.
 Because of their biological stability and role in cancer patho-
biology  ( 1–3 ) , microRNAs (miRNAs) have substantial potential 
as cancer biomarkers  ( 4,5 ) . Th e miRNAs are short, noncoding 
RNAs consisting of 18–25 nucleotides that function by targeting 
specifi c mRNA moieties for translational repression or degrada-
tion, thereby regulating several biological processes including cell 
proliferation, migration, invasion, survival, and metastasis  ( 6–9 ) . 
Th e miRNAs have also been implicated in the modulation of 
PDAC progression and patient survival  ( 10–16 ) . Th e majority of 
studies evaluating miRNAs in PDAC are derived from surgical tis-
sue samples; nearly 100 miRNAs have been identifi ed by their dif-
ferential expression in PDAC tissue  ( 10–18 ) . For maximal utility 
in the clinical setting—screening, treatment planning, and assess-
ment of treatment response—the optimal PDAC biomarker(s) 
would be identifi ed from a blood sample, and following referral 
for specialized endoscopic procedures, biomarkers could be read-
ily assayed in bile or pancreatic juice aspirates, or PDAC tissue 
obtained by fi ne-needle aspirate.
 Th e primary objective of this pilot study was to assess the utility 
of select miRNAs as diagnostic markers for diff erentiating PDAC 
from CP and from individuals without pancreatic disorders by 
comparing the diff erential expression of miRNAs in plasma and 
bile among individuals with PDAC, CP, and normal pancreas. 
Secondarily, we describe the diff erential expression of miRNAs 
in the subgroup of individuals having pancreatic juice samples 
available for analysis.
 METHODS
 Patient cohort
 We selected patients from a cohort who had been prospectively 
enrolled between July 2012 and February 2014 into a Pancreato-
biliary Diseases Database and Biological Repository at Indiana 
University School of Medicine. Th is database includes individu-
als with PDAC, CP, or other benign pancreatobiliary diseases 
undergoing endoscopic ultrasound (EUS) or endoscopic retro-
grade cholangiopancreatography (ERCP) at Indiana University 
Health University Hospital, Indianapolis, Indiana. Th is represents 
a tertiary referral center for individuals with advanced pancreatic 
disease such as CP and PDAC. From this Repository, we selected 
patients having available plasma, bile, pancreatic juice, or some 
combination. All samples were procured immediately before or 
during their endoscopy.
 We included all patients in the Repository with a confi rmed 
tissue diagnosis of PDAC and no prior therapy for PDAC. To 
develop and validate the PDAC Signature Panel for diagnosing 
PDAC, we established a training cohort and a validation cohort 
derived from the Repository. To reduce the confounding eff ect 
of age on diagnostic accuracy of miRNAs, we designed the train-
ing cohort to include a random subgroup of the individuals with 
PDAC and an age-matched sample of individuals enrolled into the 
Repository having a confi rmation of CP or other benign biliary 
disorders (controls) with available specimens for analysis using the 
frequency matching scheme. All patients with CP were undergo-
ing ERCP for the treatment of bile or pancreatic duct pathology 
(i.e., strictures). All patients classifi ed as controls were undergo-
ing ERCP for the treatment of choledocholithiasis. Th e sample size 
targeted for the training cohort was chosen to provide >80% power 
to detect a diff erence of 0.1 in diagnostic accuracy, indicated by 
the area under the receiver operating characteristic (ROC) curve, 
for distinguishing PDAC and other patients using plasma miR-
NAs in comparison with carbohydrate antigen 19-9 (CA19-9). 
We assumed an α -level of 0.1 because of the exploratory nature 
of the study. Th e diagnostic accuracy of CA19-9 was assumed to 
have an area under the ROC curve (AUC) of 0.85 based on pre-
vious research  ( 19,20 ) . To validate the diagnostic performance 
of a miRNA Panel developed from the training cohort, we then 
established a validation cohort comprising individuals having the 
same diagnoses using a separate, random sample derived from the 
Repository, where patients were not age matched so that the data 
represent a real-world cohort of individuals presenting for EUS, 
ERCP, or both with suspected PDAC, CP, and choledocholithiasis.
 Relevant clinical data were collected at the time of the procedure, 
and a diagnosis of PDAC required cytopathological confi rmation. 
All individuals with PDAC were enrolled before the initiation of 
therapy (treatment naive). Individuals with CP were classifi ed by 
the Cambridge criteria on computed tomography, ERCP, or both 
 ( 21 ) . Control subjects had previously undergone normal cross-
sectional imaging of the pancreas. Before subject enrollment, our 
local Institutional Review Board approved this study protocol and 
each subject signed informed consent.
 Sample procurement
 Aft er signing consent and before the onset of endoscopy, no more 
than 20 ml of blood was collected and equally distributed into 
EDTA-coated tubes. Among subjects undergoing ERCP, 1–5 ml 
of bile and/or pancreatic juice was aspirated and collected in an 
uncoated tube. Specimens were initially stored at 4–8 °C, and 
then rapidly processed by centrifugation followed by collection 
of supernatant. Aft er processing, all supernatants were stored at 
−80 °C until analysis.
 Rationale for miRNA selection and assay methodology
 Investigators analyzing samples (A.J.G., S.D.M., and M.K.) were 
blinded to the underlying diagnosis. Based on previous studies 
by our group and others, we assayed plasma, pancreatic juice, 
and bile aspirates for 10 miRNA candidates (miR-10b, -21, -30c, 
-106b, -132, --155, -181a, -181b, -196a, and -212) having a known 
or suspected association with PDAC. Each of these miRNAs are 
overexpressed in PDAC or have been linked mechanistically to 
RB dysfunction or the epidermal growth factor receptor, both 
of which have crucial roles in PDAC pathobiology  ( 22–32 ) . 
Compared with normal or CP patients, we previously reported 
elevation in miRNA-10b levels in archival plasma samples from 
individuals with PDAC  ( 12 ) . Importantly, miRNA-10b is one of 
the most frequently upregulated miRNAs in PDAC, and we have 
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previously utilized biopsies from EUS-derived fi ne-needle aspi-
rates to correlate decreased miRNA-10b expression in the cancer 
cells in PDAC with improved survival, response to neoadjuvant 
radiochemotherapy, and delayed time to metastasis  ( 29 ) . Th ere-
fore, we hypothesized that these 10 plasma miRNAs would repre-
sent a broad variety of functions in PDAC and had high potential 
for release into the circulation. Th e rationale for including bile and 
pancreatic juice is that many patients with PDAC and CP present 
with bile or pancreatic duct obstruction. Th is usually prompts 
ERCP for drainage and intraductal tissue sampling in conjunc-
tion with EUS-derived fi ne-needle aspirates. Tissue sampling is 
operator dependent and cytopathology inaccurate in the setting 
of CP, and hence a diagnostic test requiring aspiration of bile or 
pancreatic juice would be clinically useful in certain cases.
 Total RNA was isolated from samples using Trizol-LS (Life Tech-
nologies, Carlsbad, CA). Complementary DNA was generated 
using 10 ng of RNA in conjunction with miRNA-10b, -21, -30c, 
-106b, -132, -155, -181a, -181b, -196a, -212, or -425-5p reverse 
transcription primers and a miRNA reverse transcription kit (Life 
Technologies) according to the manufacturer’s recommendations. 
Quantitative PCR was performed for each miRNA using Taqman 
(Life Technologies, Grand Island, NY) miRNA expression assay 
reagents. Expression levels for all candidate miRNAs were normal-
ized to miRNA-425-5p that was expressed at similar levels in all 
samples, exhibiting <1 cycle threshold (Ct) diff erence across the 
samples  ( 31 ) . MiRNA-16, -23a, and -93 were evaluated as endog-
enous controls, but these miRNAs exhibited greater intersample 
variability than miR-425-5p. Aft er normalization to miR-425-5p 
(Δ Ct), the Δ Ct values for miRNAs in controls were averaged and 
subtracted from the Δ Ct values of each individual sample (Δ Δ Ct) 
and expression levels were calculated using the 2 −Δ Δ Ct method 
that indicates a twofold diff erence per every diff erence in normal-
ized Ct values  ( 32 ) .
 Statistical analysis
 Sample characteristics, laboratory characteristics, and miRNA 
expression levels of patients in the PDAC, CP, and control groups 
were compared using analysis of variance for normally distrib-
uted continuous variables, nonparametric Kruskal–Wallis tests 
for nonnormally distributed continuous variables, and Pear-
son’s χ 2 tests for categorical variables. Descriptive statistics were 
reported using mean±s.d. for normally distributed, continu-
ous variables and median/interquartile range for non-normally 
distributed continuous variables. For each variable, pairwise 
comparison was performed with  P values adjusted using the 
Bonferroni approach  ( 33 ) .
 Th e fi rst step in the development of the PDAC Signature Panel 
involved bivariable analyses using logistic regression in the train-
ing cohort in order to determine the relationship between expres-
sion level of each miRNA and presence/absence of PDAC (PDAC 
vs. CP or control). Predictive performance of each miRNA was 
described using the ROC curve and the AUC, with excellent 
accuracy defi ned as AUC >0.90. We also evaluated the predictive 
performance of each miRNA in discriminating PDAC vs. 
CP, PDAC vs. control, and CP vs. control. In order to explore 
dichotomization of the expression level, miRNAs having excellent 
accuracy in bivariate analysis of PDAC prediction were further 
examined using a classifi cation tree model.
 Multivariable analyses were then performed using logistic 
regression in which dichotomized expression levels of all miRNAs 
with excellent accuracy were included in a forward stepwise selec-
tion procedure ( P <0.20 for entering and staying in the model) to 
determine the fi nal predictors for the PDAC Signature Panel. We 
chose  P <0.20 in the multivariable model because of the explora-
tory nature of the analyses. Finally, we constructed a point scoring 
system in which points were assigned to miRNAs using coeffi  cients 
from the fi nal logistic regression model. We calculated points asso-
ciated with each miRNA by dividing the corresponding coeffi  cient 
by the lowest coeffi  cient in the fi nal model and rounding to the 
nearest integer. We then computed the Panel score for each patient 
by adding the points for all miRNAs in the fi nal model. Th e PDAC 
Signature Panel scoring system was repeated using plasma alone 
and bile alone.
 To validate the PDAC Signature Panel, we applied the point 
scoring system constructed in the training cohort to the validation 
cohort by determining the risk points for each patient in the vali-
dation cohort. Performance of these Signature Panels was evalu-
ated using sensitivity and specifi city.
 As there were limited pancreatic juice samples from patients, we 
describe the diff erential expression of miRNAs using data derived 
from both training and validation cohorts for patients with PDAC 
and CP in the secondary analysis. In addition, for descriptive 
purposes, we measured diff erences in miRNA expression among 
PDAC individuals having metastatic (stage IV) and nonmetastatic 
(stage I–III) disease. Statistical analysis was performed using SAS 
v. 9.3 (Cary, NC) and R Project soft ware (Vienna, Austria).
 RESULTS
 Study population
 Th e study included a total of 215 individuals identifi ed in the Bio-
logical Repository, with 95 subjects comprising the training and 
120 comprising the validation cohort ( Figure 1 ). Of individu-
als with PDAC, 53/77 (69%) were staged T1–T3 at the time of 
specimen procurement. Clinical characteristics are summarized 
in  Table 1 . Th ere were no signifi cant diff erences in age and sex in 
the training cohort; in the validation cohort, subjects with PDAC 
were signifi cantly older. Tobacco use was less prevalent among 
control subjects in the training cohort, but similar between PDAC 
and CP individuals; there were no diff erences in miRNA expres-
sion based on tobacco use ( Supplementary Figure S1 online). 
Alcohol use was less prevalent among control subjects in the vali-
dation cohort, but similar between PDAC and CP individuals in 
both the training and validation cohorts.
 Laboratory characteristics at the time of specimen procurement 
are summarized in  Table 2 . We did not perform comparative sta-
tistics for CA19-9 because values were only available for individu-
als with PDAC. Compared with individuals with CP and controls, 
median serum bilirubin and the proportion of cases having at 
least mild elevation in serum bilirubin (defi ned as >2 mg/dl) 
© 2014 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY
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were signifi cantly greater in PDAC cases. However, the inclu-
sion of serum bilirubin as a potential confounding variable did 
not aff ect miRNA expression ( Supplementary Figure S2 ) or the 
performance of our diagnostic panels detailed below. Observed 
diff erences in serum albumin and total protein were not clini-
cally relevant (diff erences <1.0 for each measure), and white blood 
count and calcium levels were similar across groups.
 MiRNA expression
 We evaluated 10 miRNAs in plasma and bile in the training 
cohort: plasma was available for analysis in all but 1 control 
and bile in all but 15 PDAC, 7 CP, and 3 controls ( Figure 2 and 
 Supplementary Table S1 ). Of the plasma miRNAs, only miRNA-
21 was similar across groups ( P =0.426). MiRNA-10b, -30c, -106b, 
-155, -181b, -196a, and -212 were signifi cantly diff erent across all 
three groups with a  P value of <0.001 and between individuals 
with PDAC and CP ( P <0.001). MiRNA-132 and -181a were also 
signifi cantly diff erent across all three groups ( P =0.001 and 0.007, 
respectively), with statistically signifi cant diff erences persisting 
in pairwise comparison of PDAC and CP for only miRNA-181a 
( P =0.016). In bile, all miRNAs were signifi cantly diff erent across 
groups except for miRNA-21 ( P =0.151), miRNA-132 ( P =0.535), 
and miRNA-181b ( P =0.297). Diff erences in miRNA expression 
in bile persisted in pairwise comparisons of PDAC vs. CP except 
for miRNA-181a ( P =0.115) and miRNA-196a ( P =0.198); in pair-
wise comparisons of PDAC vs. control, diff erences in bile miRNA 
expression persisted. Th e accuracy of each miRNA in distinguish-
ing PDAC from CP and controls is illustrated by ROC curves 
( Figure 3 ).
 Compared with PDAC individuals with stage I–III disease 
( n =53), those having stage IV disease at the time of specimen 
procurement ( n =17, with 7 individuals lacking stage data) had 
similar plasma miRNA profi les for each of the 10 miRNAs meas-
ured. Although not meeting statistical signifi cance, median (inter-
quartile range) expression of miRNA-132 ( n =24) was higher 
among subjects with stage IV disease (2.01 (1.44) vs. 0.57 (1.58), 
 P =0.0926); miRNA-155 and -181b expression in bile ( n =24) was 
lower among subjects with stage IV disease (miRNA-155: 14.59 
(18.29) vs. 24.7 (20.9),  P =0.0792; miRNA-181b: 0.62 (0.84) vs. 1.22 
(0.82),  P =0.0448). All other bile miRNAs were expressed similarly 
between those with stage IV and I–III disease.
 PDAC Signature Panel
 Bivariable logistic regression analyses showed that 5 miRNAs 
(miRNA-10b, -30c, -106b, -155, and -212) in plasma and bile pro-
vided excellent accuracy (AUC >0.90) for distinguishing PDAC 
patients from others (CP+control) based on the training cohort 
( Supplementary Table S2 ). Th ese miRNAs also provided excel-
lent accuracy for distinguishing PDAC from controls. In addi-
tion, each miRNA had good (plasma miRNA-212, defi ned as 
AUC >0.80) or excellent (all other plasma miRNAs and all fi ve 
bile miRNAs) accuracy in distinguishing PDAC from CP sub-
jects. Th erefore, we selected these miRNAs to build a PDAC Sig-
nature Panel. Based on classifi cation tree analyses, the thresholds 
for dichotomizing the expression levels were 3.579, 4.873, 2.920, 
10.680, and 2.013 for plasma miRNA-10b, -30c, -106b, -155, and 
-212, respectively. For the same fi ve miRNAs derived from bile, 
thresholds were 3.497, 3.933, 5.261, 5.232, and 4.163, respectively. 
Considering these thresholds, the sensitivity and specifi city of 
these miRNAs derived from plasma and bile are computed and 
summarized in  Table 3 .
 Assays of plasma and bile for miRNA-10b, -155, -106b, -30c, and 
-212 using samples derived from the validation cohort were per-
formed similar to the training cohort ( Figure 4 ). Using the dichot-
omized diff erential miRNA expression level in the training cohort, 
we constructed PDAC Signature Panels using plasma miRNAs 
alone and bile miRNAs alone ( Table 4 ). Using plasma miRNAs 
alone, forward stepwise selection procedure selected miRNA-
10b and -106b, with the other three miRNAs dropping from the 
model for  P value >0.20 because of high correlation between each 
of the miRNA. Based on coeffi  cients derived from the fi nal logis-
tic regression model including plasma miRNA-10b (parameter 
estimate±s.e. 3.83±1.87,  P =0.0405) and miRNA-106b (5.18±1.87, 
 P =0.0055), we assigned 1 point for high miRNA-10b (>3.579) and 
1 point for high miRNA-106b (>2.920). Using a plasma Panel score 
of ≥2 to diagnose PDAC, we have 38/40=95% sensitivity (95% con-
fi dence interval (CI), 83–99%), 54/54=100% specifi city (95% CI, 
93–100%), positive likelihood ratio 103.6 (95% CI, 6.6–1,637), 
Cohort
(n =215)
Training
(n =95)
PDAC
(n =40)
Stages I–III
(n =25)
Stage IV
(n =14)
Stages I–III
(n =28)
Stage IV
(n =3)
CP
(n =30)
Control
(n =25)
PDAC
(n =37)
CP
(n =37)
Control
(n =46)
Validation
(n =120)
 Figure 1 .  Study population ( n =215). CP, chronic pancreatitis; PDAC, pancreatic ductal adenocarcinoma. Seven subjects with PDAC have missing stage 
information in the training ( n =1) and validation ( n =6) cohorts.
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threshold bile Panel score ≥1, we have 24/25=96% sensitivity (95% 
CI, 80–100%), 45/45=100% specifi city (95% CI, 92–100%), posi-
tive likelihood ratio 87.4 (95% CI, 5.5–1,378.2), and negative like-
lihood ratio 0.06 (95% CI, 0.01–0.28) in the training cohort and 
28/28=100% sensitivity (95% CI, 88–100%), 61/61=100% specifi c-
ity (95% CI, 94–100%), positive likelihood ratio 123 (95% CI, 7.8–
1,944.4), and negative likelihood ratio 0.02 (95% CI, 0.001–0.27) in 
the validation cohort ( Table 4 ).
 Th e inclusion of serum bilirubin in regression models (i.e., 
controlling for diff erences in serum bilirubin) did not aff ect the 
performance characteristics of our PDAC Panels using plasma 
( P =0.73 for serum bilirubin) or bile miRNA ( P =0.92 for serum 
bilirubin).
and negative likelihood ratio 0.06 (95% CI, 0.02–0.21) in the 
training cohort and 29/29=100% sensitivity (95% CI, 88–100%), 
75/75=100% specifi city (95% CI, 95–100%), positive likelihood 
ratio 151 (95% CI, 9.5–2,392), and negative likelihood ratio 0.02 
(95% CI, 0.001–0.26) in the validation cohort.
 We constructed a similar model using bile miRNA alone. Th e 
forward stepwise selection procedure confi rmed that the dichoto-
mized expression level of each of the fi ve miRNAs performed iden-
tically in distinguishing PDAC from other etiologies. Th e addition 
of two or more bile miRNAs did not improve the performance of 
the Panel. Th erefore, we assigned one point to a patient if any of the 
following miRNAs exceeded their threshold score: miRNA-10b 
(>3.497), -106b (5.261), -155 (5.232), and -212 (>4.163). Using a 
 Table 1 .  Patient characteristics 
 Variable  PDAC  CP  Control  P  value  PDAC vs. CP  PDAC vs. control  CP vs. control 
 Training cohort  N =40  N =30  N =25     
 Age, mean (s.d.) a  66.5 (9.8)  64.0 (10.4)  66.4 (10.8)  0.567    
 Female sex,  n (%)  24 (60%)  15 (50%)  15 (60%)  0.658    
  Tobacco use, status, n  (%) 
  Never  18 (47.4%)  6 (21.4%)  13 (61.9%)  0.012  0.083  1.000  0.016 
  Ever  13 (34.2%)  9 (32.1%)  6 (28.6%)     
  Current  7 (18.4%)  13 (46.4%)  2 (9.5%)     
  Alcohol use, status 
  Never  20 (51.3%)  15 (55.6%)  17 (81%)  0.084    
  Ever  13 (33.3%)  11 (40.7%)  3 (14.3%)     
  Current  6 (15.4%)  1 (3.7%)  1 (4.8%)     
 Tobacco and alcohol 
use,  n (%) 
 13 (35.1%)  12 (44.4%)  2 (9.5%)  0.030  1.000  0.097  0.025 
 Validation cohort  N =37  N =37  N =46 
 Age, mean (s.d.)  65.2 (11.9)  47.7 (12.2)  48.8 (15.8)  <0.001  <0.001  <0.001  1.000 
 Female sex,  n (%)  18 (48.7%)  19 (51.4%)  31 (67.4%)  0.170    
  Tobacco use, status, n  (%) 
  Never  13 (35.1%)  8 (21.6%)  15 (33.3%)  0.274    
  Ever  13 (35.1%)  9 (24.3%)  14 (31.1%)     
  Current  11 (29.8%)  20 (54.1%)  16 (35.6%)     
  Alcohol use, status 
  Never  22 (61.1%)  15 (40.5%)  33 (73.3%)  0.030  0.455  1.000  0.018 
  Ever  9 (25%)  17 (46%)  7 (15.6%)     
  Current  5 (13.9%)  5 (13.5%)  5 (11.1%)     
 Tobacco and alcohol 
use,  n (%) 
 11 (30.6%)  21 (56.8%)  10 (22.2%)  0.004  0.072  1.000  0.004 
 CP, chronic pancreatitis; PDAC, pancreatic ductal adenocarcinoma. 
 We compare continuous variables that are normally distributed using analysis of variance (ANOVA) (age), likelihood ratio χ 2 test for categorical variables having low 
expected cell counts, and other variables using Pearson’s χ 2 test. Pairwise comparisons were performed using the Bonferroni multiple comparison approach. 
 a To minimize the potential of age being a confounder in microRNA (miRNA) expression between groups, subjects were age matched in the training cohort. 
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 Pancreatic juice
 As pancreatic juice was available in a limited number of indi-
viduals with PDAC ( n =9) and CP ( n =34) in the entire cohort, 
we also present the diff erential expression of miRNA-10b, -155, 
-106b, -30c, and -212 between these groups. On univariate analy-
sis, the AUC=1.0 (100% accuracy in distinguishing PDAC from 
CP) for all miRNAs in the Signature Panel except miRNA-30c 
(AUC=0.941). Th resholds based on the classifi cation tree were 
4.42 for miRNA-155, 4.54 for miRNA-106b, 3.41 for miRNA-10b, 
3.69 for miRNA-212, and 3.27 for miRNA-30c. Similar to models 
for plasma alone and bile alone, a PDAC Panel score ≥1 correctly 
diagnosed all individuals with PDAC from those with CP.
 DISCUSSION
 In their lifetime, PDAC will develop in 1 of 68 Americans, and 
only 6% of aff ected individuals will survive for 5 years  ( 34 ) . Clini-
cal trials touting the incremental benefi t of chemotherapeutic 
agents such as gemcitabine, combination of oxaliplatin/leucov-
orin/irinotecan/fl uorouracil (FOLFIRINOX)  ( 35 ) , and albumin-
bound paclitaxel  ( 36 ) report survival benefi ts that are quantifi ed 
in months. Given these dismal statistics, there is substantial 
interest in developing novel tests to identify PDAC at an earlier 
stage or even in precursor lesions such as pancreatic intraepi-
thelial neoplasia or early-stage intraductal papillary mucinous 
neoplasm  ( 37–39 ) . Th e need for superior diagnostics applies to 
patients with or without CP who present with indeterminate bile 
or pancreatic duct strictures, where ERCP-based tissue sampling 
techniques have limited sensitivity and where bile or pancreatic 
juice aspirates may apply. In addition, a peripheral biomarker for 
PDAC could be utilized as a fi rst-line test for patients present-
ing with obstructive jaundice and suspected PDAC in community 
hospitals where EUS and ERCP-based tissue sampling is unavail-
able. Th e miRNAs, which are short noncoding RNA, represent an 
attractive class of diagnostic and prognostic biomarkers for clini-
cal application as they remain stable in tissue and bodily fl uids and 
infl uence the pathobiology of cancer cells by altering the expres-
sion of various proteins such as epidermal growth factor recep-
tor. Case–control studies evaluating diff erent miRNA profi les in 
whole blood  ( 19,40 ) or plasma/serum  ( 12,27,41,42 ) have yielded 
varying results. Given the high accuracy of individual miRNA 
and the PDAC Signature Panel derived from our cohort, plasma 
appears to be a superior medium than serum  ( 41 ) or whole blood 
 ( 19,43 ) for this indication.
 Table 2 .  Laboratory characteristics 
 Variable  PDAC  CP  Normal  P  value  PDAC vs. CP  PDAC vs. normal  CP vs. normal 
 Study cohort  N=40  N=30  N=25     
 CA19-9, U/ml median (IQR)  385 (1,689)       
  Total bilirubin, mg/dl median 
(IQR) 
 5.3 (11.2)  0.6 (0.2)  0.7 (1.1)  <0.001  <0.001  0.001  1.000 
   At least mild elevation 
(bilirubin >2.0 mg/dl),  n (%) 
 20 (55.6%)  1 (3.5%)  4 (20%)  <0.001  <0.001  0.024  0.176 
  WBC, cells ×10 3 /μ l (median, 
IQR) 
 7.5 (3.1)  7.8 (2.6)  5.9 (2.5)  0.107    
 Albumin, g/dl mean (s.d.)  3.7 (0.5)  3.9 (0.6)  3.9 (0.4)  0.137    
  Total protein, g/dl mean (s.d.)  6.8 (0.8)  7.2 (0.6)  6.9 (0.5)  0.078    
 Calcium, mg/dl mean (s.d.)  9.3 (0.6)  9.4 (0.5)  9.3 (0.8)  0.674    
 Validation cohort  N=37  N=37  N=46     
 CA19-9, U/ml median (IQR)  742.5 (1,477)       
  Total bilirubin, mg/dl median 
(IQR) 
 11.6 (13)  0.4 (0.3)  0.9 (1.2)  <0.001  <0.001  <0.001  <0.001 
   At least mild elevation 
(bilirubin >2.0 mg/dl),  n (%) 
 26 (78.8%)  2 (5.4%)  9 (20.5%)  <0.001  <0.001  <0.001  0.120 
  WBC, cells ×10 3 /μ l (median, 
IQR) 
 8 (4.6)  7.6 (1.6)  7.7 (3)  0.859    
 Albumin, g/dl mean (s.d.)  3.5 (0.8)  3.9 (0.5)  3.9 (0.5)  0.005  0.039  0.005  1.000 
  Total protein, g/dl mean (s.d.)  6.5 (0.9)  6.9 (0.5)  7.2 (0.8)  0.001  0.074  <0.001  0.285 
 Calcium, mg/dl mean (s.d.)  9.1 (0.5)  9.3 (0.5)  9.4 (0.6)  0.070    
 CA19-9, carbohydrate antigen 19-9; CP, chronic pancreatitis; IQR, interquartile range; PDAC, pancreatic ductal adenocarcinoma; WBC, white blood count. 
 Continuous variables that are normally distributed are compared using analysis of variance (ANOVA; albumin, total protein, calcium) and others are compared using 
the nonparametric Kruskal–Wallis test (total bilirubin and WBC). Likelihood ratio χ 2 test was used for the categorical variable mild bilirubin elevation because of low cell 
counts. Pairwise comparisons were performed using the Bonferroni multiple comparison approach. 
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pancreatobiliary diseases, some of which (e.g., CP) may mimic 
PDAC and in whom a peripheral biomarker would be most useful. 
We deliberately chose a control population with choledocholithiasis 
as opposed to a purely healthy control population in an eff ort to 
minimize selection bias. For cancer screening, a PDAC Signature 
Panel would unlikely apply to the general population but rather 
high-risk populations such as those with a family history and CP.
 MiRNA stability in plasma, bile, and pancreatic juice
 Plasma miRNAs are stable over a wide pH range and do not 
degrade when plasma is subjected to multiple freeze/thaw cycles 
or to boiling  ( 45,46 ) . Th erefore, it is not surprising that we gener-
ated reproducible results of miRNA expression in plasma, bile, and 
pancreatic juice. Importantly, in clinical practice, patients with 
 In the present analysis, the performance of our panels that incor-
porated the diff erential expression of miRNAs, each having excel-
lent accuracy in distinguishing PDAC from controls and CP, is 
superior to historical populations using CA19-9  ( 44 ) . Th erefore, 
the current miRNA profi le may be important clinically given that 
CP patients are at risk of developing PDAC, and that CA19-9 levels 
cannot diff erentiate between PDAC and CP. A limitation of CA19-9 
is its diminished specifi city in the setting of obstructive jaundice; 
the miRNAs studied were unaff ected by the presence of jaundice 
( Supplementary Figure S2 ), and inclusion of serum bilirubin in 
our models did not signifi cantly aff ect the diagnostic accuracy of 
our panels. Our reference populations (CP patients having pan-
creatobiliary duct pathology and controls having choledocholithi-
asis) refl ect a “real-world” cohort of individuals with a variety of 
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 Table 3 .  Performance characteristics of plasma and bile miRNAs for diagnosing PDAC in the training cohort ( n =95) 
 Candidate 
miRNA 
 True positives 
( n ) 
 True negatives 
( n ) 
 False positives 
( n ) 
 False negatives 
( n ) 
 Sensitivity  Speciﬁ city  LR+  LR− 
 Plasma 
 miR-10b  38  54  0  2  95%  100%  103.6  0.06 
 miR-30c  29  52  2  11  73%  96%  15.9  0.29 
 miR-106b  40  53  1  0  100%  98%  36.3  0.09 
 miR-155  37  54  0  3  93%  100%  100.9  0.09 
 miR-212  36  45  9  4  90%  83%  5.2  0.13 
 Bile 
 miR-10b  24  45  0  1  96%  100%  87.4  0.06 
 miR-30c  24  44  1  1  96%  98%  29.1  0.04 
 miR-106b  24  45  0  1  96%  100%  87.4  0.06 
 miR-155  24  45  0  1  96%  100%  87.4  0.06 
 miR-212  24  45  0  1  96%  100%  87.4  0.06 
 LR−, negative likelihood ratio; LR+, positive likelihood ratio; miRNA, microRNA; PDAC, pancreatic ductal adenocarcinoma. 
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 We also did not observe signifi cant diff erences in the expression 
of miRNAs among PDAC individuals with stage I–III vs. stage IV 
disease. However, our cross-sectional study did not include serial 
collection of plasma to track miRNA expression following surgi-
cal resection or systemic therapy, and PDAC patient follow-up was 
relatively short. Th erefore, we cannot extrapolate whether certain 
miRNAs diff erentially expressed in plasma, bile, or pancreatic 
juice will correlate with response to specifi c therapies or survival. 
Nonetheless, the present fi ndings indicate that a plasma miRNA 
signature may serve as a noninvasive diagnostic test for PDAC, and 
that obtaining bile or pancreatic juice for miRNA during ERCP for 
the evaluation and treatment of pancreatobiliary strictures may be 
equally accurate. In addition, the current miRNA signature could 
complement recently described protein biomarkers  ( 50 ) without 
being infl uenced by jaundice or age. We deliberately chose age-
matched individuals with CP and controls in the training cohort 
to eliminate the potential for it to infl uence the results. Consistent 
with previous studies, we did not observe signifi cant diff erences in 
plasma miRNA expression among control subjects with increas-
ing age ( Supplementary Figure S3 )  ( 51,52 ) . Th e validation cohort 
represented a real-world cohort of individuals presenting for EUS, 
ERCP, or both with suspected PDAC, CP, and choledocholithiasis 
(controls); plasma and bile panels applied to this validation group 
had excellent sensitivity and specifi city for diagnosing PDAC.
 A limitation of our study is that we could not directly compare 
the performance of our PDAC Signature Panel to CA19-9—the only 
currently available peripheral biomarker for PDAC—as CA19-9 was 
unavailable for the majority of CP and control individuals. However, 
the miRNA Signature Panels developed in this study provided supe-
rior diagnostic accuracy than CA19-9 based on historical popula-
tions. Additional cohort studies are needed to confi rm whether 
our miRNA panels (plasma and bile) are superior to CA19-9 for 
diagnosing PDAC; ideally, these would be coupled with long-term 
follow-up to determine the prognostic value of selected miRNAs.
 In summary, a PDAC Signature Panel developed from the dif-
ferential expression of miRNA in plasma, bile, or pancreatic juice 
represents a promising and novel diagnostic test for PDAC. Th is 
Panel accurately distinguishes individuals with PDAC from those 
bile and pancreatic duct strictures are a diagnostic conundrum. 
ERCP- and EUS-based tissue sampling techniques have reduced 
sensitivity for distinguishing PDAC from CP and other benign 
etiologies of stricture, and hence aspiration of bile, pancreatic 
juice, or both is an attractive alternative to cholangiopancreatos-
copy and fl uorescence  in situ hybridization—current “second-
tier” diagnostic tests used in clinical practice  ( 47 ) . In addition, 
tissue sampling from the pancreas or bile duct is operator depend-
ent, whereas aspiration of bile or pancreatic juice for miRNA 
analysis could be performed by all ERCP providers. ERCP is oft en 
indicated in the setting of suspected PDAC for the palliation of 
obstructive jaundice or an indeterminate pancreatic duct stric-
ture, and hence aspiration of bile or pancreatic juice may enhance 
the diagnostic performance of this intervention.
 Analysis of miRNA expression from surgical explants indicates that 
a miRNA panel may even be able to distinguish cholangiocarcinoma 
from PDAC, and this will be increasingly important as systemic ther-
apies are personalized for these cancer subtypes  ( 48 ) . Impressively, 
the performance of plasma alone had excellent accuracy for distin-
guishing PDAC from CP and controls. Nonetheless, future studies 
should explore the potential complementary roles of plasma+bile 
miRNAs as biomarkers for diff erentiating pancreatic cancer from 
cholangiocarcinoma or metastatic lesions to the pancreas.
 Peripheral miRNA as prognostic markers
 MiRNA-10b, miR-21, and miR-155 are important in PDAC 
biology  ( 12,13,15,17,29 ) . However, miR-21 did not serve as a 
good plasma, bile, or pancreatic juice biomarker in this study. 
Th is observation underscores the fact that the mechanisms reg-
ulating miRNA release into the circulation are complex, cannot 
be generalized to all miRNAs, and have not been clearly deline-
ated. Moreover, we previously demonstrated that miRNA-10b 
and miRNA-21 are abundant in PDAC cells and are also present 
in cancer-associated fi broblasts; on the other hand, miRNA-155 
localizes to CD45+ T cells within the pancreatic tumor microen-
vironment and is not present in cancer cells  ( 29,49 ) . Th erefore, the 
cell type in which a particular miRNA is expressed in PDAC does 
not necessarily dictate its usefulness as a peripheral biomarker.
 Table 4 .  Performance characteristics of PDAC Signature Panels derived from plasma or bile 
  Plasma alone  Bile alone 
 PDAC Signature 
Panel score 
 Training 
cohort 
 Validation 
cohort 
 Training 
cohort 
 Validation 
cohort 
  Not PDAC  PDAC  Total  Not PDAC  PDAC  Total  Not PDAC  PDAC  Total  Not PDAC  PDAC  Total 
 0  53  0  53  73  0  73  45  1 (FP)  46  61  0  61 
 1  1  2 (FN)  3  2  0  2  0  24  9  0  28  28 
 2  0  38  38  0  29  29       
 Total  54  40  94  75  29  104  45  25  70  61  28  89 
 FN, false negative; FP, false positive; PDAC, pancreatic ductal adenocarcinoma. 
 Shaded boxes depict values equal to or above the threshold PDAC Signature Panel scores derived from regression models using plasma miR alone (≥2) and bile miR 
alone (≥1). 
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with CP, an at-risk population who may be considered for screen-
ing, and has substantial potential to improve the diagnostic accu-
racy of ERCP for indeterminate bile duct strictures. Future studies 
are needed to validate the diagnostic accuracy of this Panel in larger 
cohorts, as well as to assess their usefulness as markers that correlate 
with survival and response to therapy for individuals with PDAC.
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal 
cancer lacking accurate, peripheral, diagnostic markers. 
 ✓  Patients with chronic pancreatitis are at-risk for PDAC and 
represent the most challenging population to achieve a de-
fi nitive diagnosis. 
 ✓  Endoscopic retrograde cholangiopancreatography (ERCP)- 
and endoscopic ultrasound (EUS)-based tissue sampling 
techniques for bile and pancreatic duct strictures are opera-
tor dependent and have lower sensitivity in the setting of 
chronic pancreatitis. 
 ✓  Selected microRNAs (miRNAs) are diff erentially expressed 
in PDAC tissues, and there are limited data suggesting their 
diff erential expression in plasma or bile. 
 WHAT IS NEW HERE 
 ✓  Quantifi cation of miRNA-10b, -106b, -30c, -155, and -212 in 
plasma or bile has excellent accuracy in diagnosing PDAC, 
compared with individuals with chronic pancreatitis (CP) 
and controls with choledocholithiasis. 
 ✓  PDAC panels incorporating these miRNAs have >95% sensi-
tivity and specifi city for diagnosing PDAC. 
 ✓  Th e diff erential expression of selected miRNAs in bile and 
pancreatic juice appear comparable to plasma in distinguish-
ing PDAC from CP. Th is may be useful in the setting of 
indeterminate bile or pancreatic duct strictures. 
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